{
    "Trade/Device Name(s)": [
        "Atellica\u00ae CH Diazo Direct Bilirubin (D_DBil)"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K223078",
    "Predicate Device Reference 510(k) Number(s)": [
        "K053132"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CIG"
    ],
    "Summary Letter Date": "February 21, 2023",
    "Summary Letter Received Date": "February 21, 2023",
    "Submission Date": "June 9, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1110"
    ],
    "Regulation Name(s)": [
        "Bilirubin (Total Or Direct) Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Direct bilirubin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube",
        "Sodium heparin tube",
        "Dipotassium EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Atellica\u00ae CH Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Photometric test"
    ],
    "Methodologies": [
        "Diazo colorimetry"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for Atellica CH Diazo Direct Bilirubin assay for quantitative determination of direct bilirubin in human serum and plasma using photometric diazo colorimetry.",
    "Indications for Use Summary": "For in vitro diagnostic use in the quantitative determination of direct bilirubin in human serum and plasma using the Atellica CH Analyzer to aid diagnosis and treatment of liver, hemolytic-hematological, and metabolic disorders including hepatitis and gall bladder block.",
    "fda_folder": "Clinical Chemistry"
}